NDAORALTABLET, EXTENDED RELEASE
Approved
Jul 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
3/8 — Basic
ZITUVIMET XR (sitagliptin and metformin hydrochloride) by Aurobindo Pharma is dipeptidyl peptidase 4 inhibitors [moa]. First approved in 2024.
Drug data last refreshed 9h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZITUVIMET XR is a fixed-dose combination oral tablet combining sitagliptin (a DPP-4 inhibitor) and metformin hydrochloride (an extended-release formulation) for type 2 diabetes management. It works by increasing incretin hormone activity to improve glucose control while reducing hepatic glucose production. This combination targets patients requiring dual therapy for glycemic control.
Growth
Recent 2024 approval positions this product in early growth phase with expanding market penetration; expect moderate-sized commercial team focused on rapid uptake among type 2 diabetes prescribers.
Mechanism of Action
Dipeptidyl Peptidase 4 Inhibitors
Pharmacologic Class:
Dipeptidyl Peptidase 4 Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Relative to Originator
Started Jun 2024
34 enrolled
Healthy Subjects
Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Relative to Originator
Started Apr 2024
34 enrolled
Healthy Subjects
Career Relevance
ZITUVIMET XR offers entry and mid-career opportunities in commercial execution within the high-volume type 2 diabetes market; however, the mature competitive landscape and lack of clinical expansion programs limit long-term career differentiation. Professionals should expect roles focused on market penetration, payer negotiation, and sales enablement rather than innovation-driven advancement.
Worked on ZITUVIMET XR at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.